Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, March 28, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ____________________ TO ____________________ Commission File Number 001-41551 Acrivon Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) | D ...

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed for superior single-agent efficacy [1][2] - The company utilizes its proprietary AP3 platform to identify patient responders and mechanisms of drug resistance, enhancing the potential for effective cancer treatments [6] Group 1: Product Development - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at addressing limitations of existing WEE1 and PKMYT1 inhibitors [2] - Acrivon is also advancing ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for specific cancer types [6] Group 2: Research Presentation - Acrivon will present data at the AACR Annual Meeting from April 5-10, 2024, showcasing the potential of ACR-2316 and insights from the AP3 platform regarding resistance mechanisms to ACR-368 [1][3] - The presentations will include a poster on ACR-2316's design and efficacy, as well as findings on overcoming resistance to ACR-368 through combination treatments [3][4]

Core Insights - Acrivon Therapeutics is advancing ACR-2316, a selective dual WEE1 and PKMYT1 inhibitor, demonstrating strong preclinical activity and designed using the AP3 platform for enhanced single-agent efficacy [1][2] - The company will present data at the AACR Annual Meeting in April 2024, showcasing the broad applicability of its AP3 technology and its potential to address drug resistance mechanisms [2][3] Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, utilizing its proprietary AP3 platform to match treatments to patients based on tumor sensitivity [1][6] - The AP3 platform measures compound-specific effects on tumor cell protein signaling networks and drug resistance mechanisms, facilitating drug design optimization and patient identification for specific therapies [6] Pipeline and Development - Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial with Fast Track designation from the FDA for platinum-resistant ovarian or endometrial cancer [6] - ACR-2316 is the first fully internally-discovered candidate from Acrivon, generated through co-crystallography-based drug design, aimed at overcoming limitations of existing WEE1 and PKMYT1 inhibitors [2][6] Upcoming Presentations - Acrivon will present two key datasets at the AACR Annual Meeting: one on ACR-2316's design and efficacy, and another on the mechanism of resistance to ACR-368 and a combination treatment strategy [3][6]

WATERTOWN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Ivana Magovčević-Liebisch, P ...

Core Insights - Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3) [1][3] - The company has granted an equity award in the form of stock options to an employee as part of its 2023 Inducement Plan, with options to purchase 99,300 shares of common stock [2] Company Overview - Acrivon utilizes the AP3 platform to identify patients whose tumors are predicted to be sensitive to specific medicines, optimizing drug design and identifying rational drug combinations [3] - The lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer [3] - The ACR-368 OncoSignature test, which is still awaiting regulatory approval, has been evaluated in preclinical studies and has received Breakthrough Device designation from the FDA [3] - Acrivon is also developing additional preclinical stage programs, including ACR-2316, a selective dual WEE1/PKMYT1 inhibitor [3]

Company Overview - Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3) [2] - The AP3 platform identifies patients whose tumors are predicted to be sensitive to specific medicines by measuring compound-specific effects on tumor cell protein signaling networks and drug-induced resistance mechanisms [2] Key Developments - Acrivon is advancing its lead candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial across multiple tumor types [2] - The FDA has granted Fast Track designation for ACR-368 as monotherapy for patients with platinum-resistant ovarian or endometrial cancer based on OncoSignature-predicted sensitivity [2] - ACR-368's OncoSignature assay has received Breakthrough Device designation from the FDA for identifying ovarian cancer patients who may benefit from ACR-368 treatment [2] Upcoming Events - The company's president and CEO, Peter Blume-Jensen, will present an overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024 [1]

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41551 Acrivon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to __________________ Commission File Number: 001-41551 Acrivon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Dela ...